BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Fundamental Analysis & Valuation

BIT:1BMRN • US09061G1013

Current stock price

48.12 EUR
-2.58 (-5.09%)
Last:

This 1BMRN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1BMRN.MI Profitability Analysis

1.1 Basic Checks

  • 1BMRN had positive earnings in the past year.
  • 1BMRN had a positive operating cash flow in the past year.
  • 1BMRN had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years 1BMRN had a positive operating cash flow.
1BMRN.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMRN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 6.83%, 1BMRN belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
  • The Return On Equity of 1BMRN (8.59%) is better than 80.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.69%, 1BMRN belongs to the top of the industry, outperforming 84.71% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1BMRN is significantly below the industry average of 10.61%.
  • The 3 year average ROIC (3.73%) for 1BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROIC 7.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1BMRN.MI Yearly ROA, ROE, ROIC1BMRN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • The Profit Margin of 1BMRN (16.82%) is better than 82.35% of its industry peers.
  • The Operating Margin of 1BMRN (20.21%) is better than 83.53% of its industry peers.
  • Looking at the Gross Margin, with a value of 81.32%, 1BMRN is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 1BMRN has remained more or less at the same level.
Industry RankSector Rank
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
1BMRN.MI Yearly Profit, Operating, Gross Margins1BMRN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. 1BMRN.MI Health Analysis

2.1 Basic Checks

  • 1BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for 1BMRN has been increased compared to 1 year ago.
  • The number of shares outstanding for 1BMRN has been increased compared to 5 years ago.
  • 1BMRN has a better debt/assets ratio than last year.
1BMRN.MI Yearly Shares Outstanding1BMRN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1BMRN.MI Yearly Total Debt VS Total Assets1BMRN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 5.44 indicates that 1BMRN is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.44, 1BMRN is doing good in the industry, outperforming 78.82% of the companies in the same industry.
  • 1BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
  • 1BMRN's Debt to FCF ratio of 0.72 is amongst the best of the industry. 1BMRN outperforms 85.88% of its industry peers.
  • 1BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
  • 1BMRN has a better Debt to Equity ratio (0.10) than 63.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Altman-Z 5.44
ROIC/WACC0.92
WACC8.4%
1BMRN.MI Yearly LT Debt VS Equity VS FCF1BMRN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 4.83 indicates that 1BMRN has no problem at all paying its short term obligations.
  • 1BMRN's Current ratio of 4.83 is fine compared to the rest of the industry. 1BMRN outperforms 78.82% of its industry peers.
  • A Quick Ratio of 3.10 indicates that 1BMRN has no problem at all paying its short term obligations.
  • 1BMRN's Quick ratio of 3.10 is fine compared to the rest of the industry. 1BMRN outperforms 68.24% of its industry peers.
Industry RankSector Rank
Current Ratio 4.83
Quick Ratio 3.1
1BMRN.MI Yearly Current Assets VS Current Liabilites1BMRN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1BMRN.MI Growth Analysis

3.1 Past

  • 1BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
  • The Revenue has grown by 12.39% in the past year. This is quite good.
  • Measured over the past years, 1BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%

3.2 Future

  • Based on estimates for the next years, 1BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
  • The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1BMRN.MI Yearly Revenue VS Estimates1BMRN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
1BMRN.MI Yearly EPS VS Estimates1BMRN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. 1BMRN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 21.58, 1BMRN is valued on the expensive side.
  • Based on the Price/Earnings ratio, 1BMRN is valued cheaper than 84.71% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of 1BMRN to the average of the S&P500 Index (24.88), we can say 1BMRN is valued inline with the index average.
  • 1BMRN is valuated correctly with a Price/Forward Earnings ratio of 12.35.
  • Based on the Price/Forward Earnings ratio, 1BMRN is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
  • 1BMRN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 21.58
Fwd PE 12.35
1BMRN.MI Price Earnings VS Forward Price Earnings1BMRN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 1BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BMRN is cheaper than 83.53% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, 1BMRN is valued cheaper than 94.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.34
EV/EBITDA 14
1BMRN.MI Per share data1BMRN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1BMRN has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as 1BMRN's earnings are expected to grow with 35.45% in the coming years.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y44.96%
EPS Next 3Y35.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1BMRN.MI Dividend Analysis

5.1 Amount

  • No dividends for 1BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1BMRN.MI Fundamentals: All Metrics, Ratios and Statistics

BIOMARIN PHARMACEUTICAL INC

BIT:1BMRN (1/23/2026, 7:00:00 PM)

48.12

-2.58 (-5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)02-25
Inst Owners97.82%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap9.24B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target80.11 (66.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.74%
PT rev (3m)-2.74%
EPS NQ rev (1m)-29.03%
EPS NQ rev (3m)-24.43%
EPS NY rev (1m)-5.52%
EPS NY rev (3m)-16.53%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)0.77%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 21.58
Fwd PE 12.35
P/S 3.56
P/FCF 13.34
P/OCF 12.06
P/B 1.82
P/tB 1.96
EV/EBITDA 14
EPS(TTM)2.23
EY4.63%
EPS(NY)3.9
Fwd EY8.1%
FCF(TTM)3.61
FCFY7.49%
OCF(TTM)3.99
OCFY8.3%
SpS13.51
BVpS26.45
TBVpS24.58
PEG (NY)0.76
PEG (5Y)N/A
Graham Number36.43
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROCE 9.17%
ROIC 7.69%
ROICexc 9.82%
ROICexgc 10.68%
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
FCFM 26.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Debt/EBITDA 0.84
Cap/Depr 106.6%
Cap/Sales 2.85%
Interest Coverage 85.91
Cash Conversion 129.08%
Profit Quality 158.68%
Current Ratio 4.83
Quick Ratio 3.1
Altman-Z 5.44
F-Score8
WACC8.4%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%

BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to 1BMRN.MI.


What is the valuation status for 1BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (1BMRN.MI). This can be considered as Undervalued.


What is the profitability of 1BMRN stock?

BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for 1BMRN stock?

The Price/Earnings (PE) ratio for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is 21.58 and the Price/Book (PB) ratio is 1.82.